ABBISKO-B(02256): ABK3376 approved by the National Medical Products Administration for IND.

ABBISKO-B (02256) announced that its subsidiary Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Pharmaceutical) has independently discovered and developed a new generation EGFR oral small molecule inhibitor, ABK3376, in collaboration with Shanghai Allist Pharmaceuticals Co., Ltd. The drug has been approved by the China National Medical Products Administration for its first phase I clinical trial in humans, for the treatment of non-small cell lung cancer with EGFR-C797S resistance mutation.